Lawmakers rake Mylan CEO Bresch over hot coals over EpiPen price hikes

Mylan NV Chief Executive Officer Heather Bresch struggled to defend herself against harsh congressional questioning at a House Oversight Committee hearing Wednesday afternoon, after the company’s price hikes on the EpiPen allergic-reaction treatment sparked public backlash.

Lawmakers repeatedly referred to Mylan MYL, +1.58% “jacking” up the EpiPen’s price over the course of a combative two-hour hearing, asking Bresch to justify the price and rebuking her repeated assertions that the company collects only a small percentage of an over-$600 list price for an EpiPen two-pack.

Though Bresch sought to deflect questioning toward her company’s efforts to improve access to the EpiPen and a complicated pharmaceutical pricing ecosystem, lawmakers instead focused on the CEO herself: her executive compensation, which outpaces Mylan’s industry standing, and a recent USA Today report highlighting the role Bresch’s mother played as leader of a national education group while promoting EpiPen access in schools.

>>> Original Source <<<